| abstract |
The present invention provides thioredoxin reductase inhibitors, in particular, apoptotic protein-forming agents derived from selenium-adapted thioredoxin reductase (SecTRAP), for use in the treatment of a cancer infiltrated in immune cells (for example, a cancer infiltrated in T cells) in a subject, in which said agents stimulate an anti-cancer immune response. The present invention also provides combinations comprising a SecTRAP forming agent and other therapeutic agents for use in the treatment of cancer. |